Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BRID
BRID logo

BRID Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Bridgford Foods Corp (BRID) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.460
1 Day change
-1.84%
52 Week Range
8.840
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Bridgford Foods Corp (BRID) is not a strong buy for a beginner, long-term investor at this time. While there are insider buying trends and modest revenue growth, the company's declining net income, EPS, and gross margin, coupled with no significant trading signals or positive news catalysts, suggest a cautious approach. The technical indicators are neutral, and there are no strong analyst upgrades or recent political trading activity to support an immediate buy decision.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 52.08, and moving averages are converging. The stock is trading near its support level (S1: 7.255), with resistance at R1: 8.225. No clear upward or downward trend is evident.

Positive Catalysts

  • Insider buying has increased significantly (336.66% over the last month). Revenue grew 5.27% YoY in Q1 2026.

Neutral/Negative Catalysts

  • Net income dropped 24.26% YoY, EPS declined 25% YoY, and gross margin fell 1.43% YoY. No recent news or significant hedge fund activity. The stock has a 50% chance of declining in the short term.

Financial Performance

In Q1 2026, revenue increased to $55.31M (+5.27% YoY), but net income dropped to -$843K (-24.26% YoY), EPS fell to -0.09 (-25% YoY), and gross margin declined to 24.17% (-1.43% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes for Bridgford Foods Corp. The provided analyst ratings and price targets pertain to BridgeBio, not BRID.

Wall Street analysts forecast BRID stock price to rise
Analyst Rating
0
Wall Street analysts forecast BRID stock price to rise
Buy
Hold
Sell
0
Current: 7.600
sliders
Low
0
Averages
0
High
0
0
Current: 7.600
sliders
Low
0
Averages
0
High
0
Wells Fargo
Tiago Fauth
Overweight
maintain
$84 -> $88
AI Analysis
2026-01-20
Reason
Wells Fargo
Tiago Fauth
Price Target
$84 -> $88
AI Analysis
2026-01-20
maintain
Overweight
Reason
Wells Fargo analyst Tiago Fauth raised the firm's price target on BridgeBio to $88 from $84 and keeps an Overweight rating on the shares. The firm notes Attruby revenues posted a solid Q4 beat, and Wells is raising its FY26 estimates by up 10%. The firm conservatively models some seasonality for Q1 but consistent quarter-over-quarter growth Q2-Q4 in 2026.
Truist
Buy
maintain
$80 -> $86
2026-01-08
Reason
Truist
Price Target
$80 -> $86
2026-01-08
maintain
Buy
Reason
Truist raised the firm's price target on BridgeBio to $86 from $80 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BRID
Unlock Now

People Also Watch